Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.64 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.64 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30195057 | 1.00 | EHMT2 (0.64) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| Phosphoric Acid SCHEMBL17592569 | 0.89 | EHMT2 (0.52) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL1271372 | 0.88 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL3978581 | 0.86 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL24599713 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL803314 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL15301017 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL16486465 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL16132722 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A | |
| SCHEMBL26969574 | 0.84 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3693391-B1 | ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2024-08-21 | — | — | EP | claimed |
| EP-3693391-A1 | ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2020-08-12 | — | — | EP | claimed |
| US-20260132220-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12492263-B2 | Anti-HER2 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250297011-A1 | Anti-B7-H4 Antibodies and Immunoconjugates | GENENTECH, INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-12281165-B2 | Anti-B7-H4 antibodies and immunoconjugates | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3693391-B1 | ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH INC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240209425-A1 | GENERATING CAPTURE PROBES FOR SPATIAL ANALYSIS | 10X GENOMICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240209425-A1 | GENERATING CAPTURE PROBES FOR SPATIAL ANALYSIS | 10X GENOMICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240110909-A1 | BIOANALYTICAL ANALYSIS OF SITE-SPECIFIC ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2012004008-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004005-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004006-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004009-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
| US-20100094020-A1 | POLYCATIONIZED PHOSPHOLIPID DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100021480-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | PEPTRON CO., LTD (KR) | 2010-01-28 | — | — | US | disclosed |
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | UNIVERSITY OF SOUTH FLORIDA | 2008-07-31 | — | — | US | disclosed |
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | UNIVERSITY OF SOUTH FLORIDA | 2008-07-31 | — | — | US | disclosed |
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | UNIVERSITY OF SOUTH FLORIDA | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492263-B2 | Anti-HER2 antibodies and immunoconjugates | ERBB2, EGFR, ERBB3 | EHMT2 1031/4885EHMT1 2274/4885APOBEC3G 1092/4885 |
| US-20080182815-A1 | Act against several infective agents, and most notably Bacillus spp. and Staphylococcus spp., including infection caused by methicillin-resistant Staphylococcus aureus (MRSA) | SQOR, TST, COASY | EHMT2 3558/4885EHMT1 3574/4885APOBEC3G 2997/4885 |
| US-20240110909-A1 | BIOANALYTICAL ANALYSIS OF SITE-SPECIFIC ANTIBODY DRUG CONJUGATES | GUSB, DNPEP, FUCA2 | EHMT2 2562/4885EHMT1 3067/4885APOBEC3G 2110/4885 |
| US-20100021480-A1 | BIOACTIVE SUBSTANCE-BLOOD PROTEIN CONJUGATE AND STABILIZATION OF A BIOACTIVE SUBSTANCE USING THE SAME | SERPINA6, CSTB, PLG | EHMT2 4036/4885EHMT1 4303/4885APOBEC3G 3337/4885 |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | EPCAM, IGSF11, FCGR3B | EHMT2 1645/4885EHMT1 2171/4885APOBEC3G 1464/4885 |
| US-20250297011-A1 | Anti-B7-H4 Antibodies and Immunoconjugates | CD44, NECTIN4, H1-4 | EHMT2 64/4885EHMT1 86/4885APOBEC3G 2045/4885 |
| US-20260132220-A1 | Cysteine Engineered Antibodies and Conjugates | IGLV6-57, GCLC, QPCTL | EHMT2 472/4885EHMT1 741/4885APOBEC3G 559/4885 |
| US-20100094020-A1 | POLYCATIONIZED PHOSPHOLIPID DERIVATIVES | PHOSPHO1, PLTP, PTDSS2 | EHMT2 2072/4885EHMT1 2588/4885APOBEC3G 2224/4885 |
| US-12281165-B2 | Anti-B7-H4 antibodies and immunoconjugates | CD44, NECTIN4, H1-4 | EHMT2 64/4885EHMT1 86/4885APOBEC3G 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.